These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 26792218)

  • 1. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
    Faivre-Finn C; Falk S; Ashcroft L; Bewley M; Lorigan P; Wilson E; Groom N; Snee M; Fournel P; Cardenal F; Bezjak A; Blackhall F
    BMJ Open; 2016 Jan; 6(1):e009849. PubMed ID: 26792218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
    Faivre-Finn C; Snee M; Ashcroft L; Appel W; Barlesi F; Bhatnagar A; Bezjak A; Cardenal F; Fournel P; Harden S; Le Pechoux C; McMenemin R; Mohammed N; O'Brien M; Pantarotto J; Surmont V; Van Meerbeeck JP; Woll PJ; Lorigan P; Blackhall F;
    Lancet Oncol; 2017 Aug; 18(8):1116-1125. PubMed ID: 28642008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
    Salem A; Mistry H; Hatton M; Locke I; Monnet I; Blackhall F; Faivre-Finn C
    JAMA Oncol; 2019 Mar; 5(3):e185335. PubMed ID: 30520977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
    Tay RY; Fernández-Gutiérrez F; Foy V; Burns K; Pierce J; Morris K; Priest L; Tugwood J; Ashcroft L; Lindsay CR; Faivre-Finn C; Dive C; Blackhall F
    Ann Oncol; 2019 Jul; 30(7):1114-1120. PubMed ID: 31020334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial.
    Yu J; Jiang L; Zhao L; Yang X; Wang X; Yang D; Zhuo M; Chen H; Huang W; Zhu Z; Zhang M; Song Y; Li Q; Ma Z; Wang Q; Qu Y; Yu R; Yu H; Zhao J; Shi A;
    Lancet Respir Med; 2024 Oct; 12(10):799-809. PubMed ID: 39146944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study.
    Hatton MQF; Lawless CA; Faivre-Finn C; Landau D; Lester JF; Fenwick J; Simões R; McCartney E; Boyd KA; Haswell T; Shaw A; Paul J
    BMJ Open; 2019 Jan; 9(1):e019903. PubMed ID: 30700475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy 
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial.
    Walls GM; Mistry H; Barlesi F; Bezjak A; Pechoux CL; O'Brien M; Van Meerbeeck JP; Blackhall F; Faivre-Finn C
    Int J Radiat Oncol Biol Phys; 2024 Aug; 119(5):1386-1390. PubMed ID: 38521132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study.
    Haslett K; Franks K; Hanna GG; Harden S; Hatton M; Harrow S; McDonald F; Ashcroft L; Falk S; Groom N; Harris C; McCloskey P; Whitehurst P; Bayman N; Faivre-Finn C
    BMJ Open; 2016 Apr; 6(4):e010457. PubMed ID: 27084277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized Trial.
    Qiu B; Li Q; Liu J; Huang Y; Pang Q; Zhu Z; Yang X; Wang B; Chen L; Fang J; Lin M; Jiang X; Guo S; Guo J; Wang D; Liu F; Chu C; Huang X; Xie C; Liu H
    Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):424-435. PubMed ID: 33992717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.
    Grønberg BH; Killingberg KT; Fløtten Ø; Brustugun OT; Hornslien K; Madebo T; Langer SW; Schytte T; Nyman J; Risum S; Tsakonas G; Engleson J; Halvorsen TO
    Lancet Oncol; 2021 Mar; 22(3):321-331. PubMed ID: 33662285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
    Salama JK; Hodgson L; Pang H; Urbanic JJ; Blackstock AW; Schild SE; Crawford J; Bogart JA; Vokes EE;
    J Thorac Oncol; 2013 Aug; 8(8):1043-9. PubMed ID: 23715301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial.
    Christodoulou M; Blackhall F; Mistry H; Leylek A; Knegjens J; Remouchamps V; Martel-Lafay I; Farré N; Zwitter M; Lerouge D; Pourel N; Janicot H; Scherpereel A; Tissing-Tan C; Peignaux K; Geets X; Konopa K; Faivre-Finn C
    J Thorac Oncol; 2019 Jan; 14(1):63-71. PubMed ID: 30391573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation 
with Concurrent Twice-daily Radiotherapy for Patients 
with Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial.
    Sheikh H; Colaco R; Lorigan P; Blackhall F; Califano R; Ashcroft L; Taylor P; Thatcher N; Faivre-Finn C
    Lung Cancer; 2011 Oct; 74(1):75-9. PubMed ID: 21353720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.
    Komaki R; Paulus R; Ettinger DS; Videtic GM; Bradley JD; Glisson BS; Langer CJ; Sause WT; Curran WJ; Choy H
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e531-6. PubMed ID: 22560543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.
    Bogart JA; Waqar SN; Mix MD
    J Clin Oncol; 2022 Feb; 40(6):661-670. PubMed ID: 34985935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey.
    Levy A; Hendriks LEL; Le Péchoux C; Falk S; Besse B; Novello S; Dingemans AC; Hasan B; Reck M; Berghmans T; Faivre-Finn C;
    Lung Cancer; 2019 Oct; 136():145-147. PubMed ID: 31520867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Waiting for Big Changes in Limited-Stage Small-Cell Lung Cancer: For Now, More of the Same.
    Deek MP; Haigentz M; Jabbour SK
    J Clin Oncol; 2023 May; 41(13):2326-2330. PubMed ID: 36821803
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.